BBOT

BRIDGEBIO ONCOLOGY THERAPEUT

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary

BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is held as common stock by 3 tracked hedge-fund managers, with a combined reported value of ~$21.20M; the largest are Ken Griffin, Izzy Englander, Renaissance Technologies. This quarter: 1 added, 2 trimmed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.

Attention · LowThis quarter · Quiet

Common-stock holders3

Congress trades0

Price$3.81vs quarter-end-50.00%

Sectors0

This quarter's moves

New0

Added1

Trimmed / sold2

Top holder

Ken Griffin

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

Investor	Period	Value	Shares	% of portfolio	Action

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.